1-(4-乙氧基-苯基)-4-羟基-1H-吡唑-3-羧酸乙酯 | 26502-58-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(4-乙氧基-苯基)-4-羟基-1H-吡唑-3-羧酸乙酯
• 英文名称: Ethyl 1-(4-ethoxyphenyl)-4-hydroxy-1H-pyrazole-3-carboxylate
• 英文别名: ethyl 1-(4-ethoxyphenyl)-4-hydroxypyrazole-3-carboxylate
• CAS: 26502-58-9
• 化学式: C₁₄H₁₆N₂O₄
• 分子量: 276.29
• InChiKey: LTNGQELIESBHOI-UHFFFAOYSA-N

物化性质

• 沸点：
  403.0±35.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  73.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• LIPASE INHIBITORS
  申请人：Grillari Johannes

  公开号：US20130210883A1

  公开（公告）日：2013-08-15

  The invention provides a compound of formula (I) as defined herein that is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, or diabetes and disorders and conditions associated therewith. The invention also provides a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. activity.

  本发明提供了一种公式（I）所定义的化合物，适用于治疗和预防诸如消瘦症、中风、动脉粥样硬化、冠状动脉疾病或糖尿病及相关疾病和症状的方法。本发明还提供了一种筛选脂肪酶抑制剂的方法，使用公式（I）的化合物，并确定其脂肪酶抑制活性。
• ATGLISTATIN AS LIPASE INHIBITOR
  申请人：Technische Universität Graz

  公开号：EP2948433B1

  公开（公告）日：2017-04-26
• MODULATION OF ADIPOSE TRIGLYCERIDE LIPASE FOR PREVENTION AND TREATMENT OF CACHEXIA, LOSS OF WEIGHT AND MUSCLE ATROPHY AND METHODS OF SCREENING THEREFOR
  申请人：Zimmerman Robert

  公开号：US20120230943A1

  公开（公告）日：2012-09-13

  The present invention relates to agents, and methods for identifying compounds, which agents and compounds are effective in the treatment, and more particularly, that inhibit cachexia, and its associated or related disorders and conditions. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by cachexia, and its associated or related disorders and conditions and/or cachexia, and its associated or related disorders and conditions, such as for example, cancer cachexia and cachexia associated with AIDS, autoimmune disorders, drug addiction, alcoholism, chronic inflammatory disorders, cirrhosis of the liver, anorexia and neurodegenerative disease. In particular, the diagnostic marker and drug target of the invention is the ATGL Lipase, which can be inhibited by e.g. siRNAs and compounds with any of the following structures (I).
• US8993509B2
  申请人：——

  公开号：US8993509B2

  公开（公告）日：2015-03-31
• US9206115B2
  申请人：——

  公开号：US9206115B2

  公开（公告）日：2015-12-08